Literature DB >> 11713584

EGFR dependent expression of STAT3 (but not STAT1) in breast cancer.

G Berclaz1, H J Altermatt, V Rohrbach, A Siragusa, E Dreher, P D Smith.   

Abstract

STAT proteins constitute a family of transcription factors whose activation by cytokine and non-cytokine receptors leads to tyrosine phosphorylation, dimerization and translocation from the cytoplasm to the nucleus. In the nucleus they activate the transcription of specific genes by binding to consensus DNA elements. STATs 1 and 3 can be activated by both cytokine and non-cytokine receptors, and bind as homodimers or heterodimers to viral simian sarcoma virus (sis)-inducible elements such as that found in the c-fos promoter. Activation of c-Src and EGF receptor tyrosine kinases is associated with progression of breast cancer. Both these events lead to activation of STAT proteins, Src kinases activate STAT3 dependent transcription in mammary epithelial cells and EGF receptor activation can lead to activation of STATs 1 and 3. STAT3 activation has been demonstrated to have a role in oncogenesis and increasingly, activated STAT proteins are found to be activated in human cancer. In this study we describe detailed immunohistochemical analysis of nuclear and cytoplasmic STATs 1 and 3 expression in primary breast carcinomas and correlate this with EGFR, HER2, p53, ER, PR, p21/waf1, Bcl-XL and Ki-67 expression. We also compared expression between normal and tumor tissue. We report here a highly significant correlation between nuclear STAT3 expression and breast cancers compared to normal tissue. We also report a very strong correlation between nuclear STAT3 and EGFR expression in breast cancers. These data clearly demonstrate a strong association between STAT3 activation and breast tumorigenesis and strengthen the assertion that STAT3 activation may play an important role in the tumorigenic conversion of breast tissue mediated by tyrosine kinase signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11713584     DOI: 10.3892/ijo.19.6.1155

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  47 in total

1.  JAK/STAT signal pathway activation promotes progression and survival of human oesophageal squamous cell carcinoma.

Authors:  Zhenbing You; Dafu Xu; Jian Ji; Wei Guo; Weiguo Zhu; Jingdong He
Journal:  Clin Transl Oncol       Date:  2012-02       Impact factor: 3.405

Review 2.  Growth factor signaling pathways as targets for prevention of epithelial carcinogenesis.

Authors:  Okkyung Rho; Dae Joon Kim; Karou Kiguchi; John Digiovanni
Journal:  Mol Carcinog       Date:  2010-07-20       Impact factor: 4.784

Review 3.  Roles and regulation of stat family transcription factors in human breast cancer.

Authors:  Charles V Clevenger
Journal:  Am J Pathol       Date:  2004-11       Impact factor: 4.307

4.  Gambogic acid inhibits STAT3 phosphorylation through activation of protein tyrosine phosphatase SHP-1: potential role in proliferation and apoptosis.

Authors:  Sahdeo Prasad; Manoj K Pandey; Vivek R Yadav; Bharat B Aggarwal
Journal:  Cancer Prev Res (Phila)       Date:  2011-04-13

5.  A small-molecule compound identified through a cell-based screening inhibits JAK/STAT pathway signaling in human cancer cells.

Authors:  Byung Hak Kim; Chang-Hong Yin; Qianxu Guo; Erika A Bach; Haeryun Lee; Claudio Sandoval; Somasundaram Jayabose; Agnieszka Ulaczyk-Lesanko; Dennis G Hall; Gyeong-Hun Baeg
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

6.  Signal transducers and activators of transcription-3 up-regulates tissue inhibitor of metalloproteinase-1 expression and decreases invasiveness of breast cancer.

Authors:  Jennifer Dien; Hesham M Amin; Neil Chiu; Winson Wong; Christine Frantz; Brian Chiu; John R Mackey; Raymond Lai
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

7.  Tissue microarray-based study of patients with lymph node-positive breast cancer shows tyrosine phosphorylation of signal transducer and activator of transcription 3 (tyrosine705-STAT3) is a marker of good prognosis.

Authors:  Amir Sonnenblick; Anat Shriki; E Galun; Jonathan H Axelrod; Hagit Daum; Yakir Rottenberg; Tamar Hamburger; Bela Mali; Tamar Peretz
Journal:  Clin Transl Oncol       Date:  2012-03       Impact factor: 3.405

8.  Honokiol inhibits epithelial-mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E-cadherin axis.

Authors:  Dimiter B Avtanski; Arumugam Nagalingam; Michael Y Bonner; Jack L Arbiser; Neeraj K Saxena; Dipali Sharma
Journal:  Mol Oncol       Date:  2014-01-15       Impact factor: 6.603

9.  Correlation of activated STAT3 expression with clinicopathologic features in lung adenocarcinoma and squamous cell carcinoma.

Authors:  Richeng Jiang; Ziliang Jin; Zhujun Liu; Leina Sun; Liuchun Wang; Kai Li
Journal:  Mol Diagn Ther       Date:  2011-12-01       Impact factor: 4.074

10.  LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.

Authors:  Li Pan; Xiang Chen; Shengling Fu; Wenying Yu; Chenglong Li; Tiffany Wang; Hui-Wen Lo; Jiayuh Lin
Journal:  Breast Cancer Res Treat       Date:  2020-04-02       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.